References
- Castori M., Sinibaldi L., Mingarelli R., Lachman R. S., Rimoin D. L., Dallapiccola B. Pachydermoperiostosis: an update. Clin Gen 2005; 68: 477–86
- Auger M, Stavrianeas N, Pachydermoperiostosis. Orphanet encyclopedia, 2004. Available from: www.orpha.net (accessed December 2006).
- White M. P. Hereditary metabolic and dysplastic skeletal disorders. Disorders of bone and mineral metabolism, 2nd edn, F. L Coe, M. J Favus. Lippincott, Williams & Wilkins, Philadelphia 2002; 937–85
- Jajic Z., Jajic I., Nemcic T. Primary hypertrophic osteoarthropathy: clinical, radiologic, and scintigraphic characteristics. Arch Med Res 2001; 32: 136–42
- Jajic I., Jajic Z., Grazio S. Minor but important symptoms and signs in primary hypertrophic osteoarthropathy. Clin Exp Rheumatol 2001; 19: 357–8
- Hughes H. E., McAlpine P. J., Cox D. W., Philipps S. An autosomal dominant syndrome with ‘acromegaloid’ features and thickened oral mucosa. J Med Genet 1985; 22: 119–25
- Pichler G., Eber E., Thalhammer G., Muntean W., Zach M. S. Arthralgia and digital clubbing in a child: hypertrophic osteoarthropathy with inflammatory pseudotumour of the lung. Scand J Rheumatol 2004; 33: 189–91
- Oikarinen A., Palatsi R., Kylmaniemi M., Keski‐Oja J., Risteli J., Kallioinen M. Pachydermoperiostosis: analysis of the connective tissue abnormality in one family. J Am Acad Dermatol 1994; 31: 947–53
- Silveri F., De Angelis R., Argentati F., Brecciaroli D., Muti S., Cervini C. Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 1996; 15: 435–9
- Silveira L. H., Martinez‐Lavin M., Pineda C., Fonseca M. C., Navarro C., Nava A. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000; 18: 57–62
- Matucci‐Cerinic M., Martinez‐Lavin M., Rojo F., Fonseca C., Kahaleh B. M. von Willebrand factor antigen in hypertrophic osteoarthropathy. J Rheumatol 1992; 19: 765–7
- Fam A. G., Chin‐Sang H., Ramsay C. A. Pachydermoperiostosis: scintigraphic, thermographic, plethysmographic, and capillaroscopic observations. Ann Rheum Dis 1983; 42: 98–102
- Matucci‐Cerinic M., Fattorini L., Gerini G., Lombardi A., Pignone A., Petrini N., et al. Colchicine treatment in a case of pachydermoperiostosis with acroosteolysis. Rheumatol Int 1988; 8: 185–8
- Kallen K. J. The role of transsignalling via the agonistic soluble IL‐6 receptor in human diseases. Biochim Biophys Acta 2002; 1592: 323–34
- Jostock T., Mullberg J., Ozbek S., Atreya R., Blinn G., Voltz N., et al. Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses. Eur J Biochem 2001; 268: 160–7
- Boyle W. J., Simonet W. S., Lacey D. L. Osteoclast differentiation and activation. Nature 2003; 423: 337–42
- Franchimont N., Wertz S., Malaise M. Interleukin‐6: an osteotropic factor influencing bone formation?. Bone 2005; 37: 601–6
- Jones S. A., Rose‐John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL‐6R/IL‐6 complex. Biochim Biophys Acta 2002; 1592: 251–63
- Kwan Tat S., Padrines M., Theoleyre S., Heymann D., Fortun Y. IL‐6, RANKL, TNF‐alpha/IL‐1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15: 49–60
- Mossetti G., Rendina D., De Filippo G., Viceconti R., Di Domenico G., Cioffi M., et al. Interleukin‐6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. Bone 2005; 36: 549–54
- Angelo L. S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007; 13: 2825–30
- Knudsen L. S., Ostergaard M., Baslund B., Narvestad E., Petersen J., Nielsen H. J., et al. Plasma IL‐6, plasma VEGF, and serum YKL‐40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol 2006; 35: 489–91
- Brandi M. L., Collin‐Osdoby P. Vascular biology and the skeleton. J Bone Miner Res 2006; 21: 183–92
- Roodman G. D. Treatment strategies for bone disease. Bone Marrow Transplant 2007; 4: 1139–46